Guardant Health has patented a method to determine the probability of a cancer patient’s response to different treatments based on genetic profiles. The method uses decision trees and machine learning algorithms to recommend the most effective treatment, aiming to maximize the patient’s chances of survival. GlobalData’s report on Guardant Health gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Guardant Health, Personalized medicine biomarkers was a key innovation area identified from patents. Guardant Health's grant share as of May 2024 was 17%. Grant share is based on the ratio of number of grants to total number of patents.
Method for determining optimal cancer treatment using probability analysis
A recently granted patent (Publication Number: US11996202B2) outlines a method that involves obtaining information about a subject, including their genetic tumor profile and past or ongoing treatments, to determine the subject's initial state. The method utilizes a decision tree with branches representing treatment options, chance nodes for uncertainty, and terminal nodes for subsequent states. Each branch and node is assigned probabilities, influenced by treatment choices and generated from a database and machine learning algorithms. The goal is to provide a treatment course that maximizes the probability of the subject achieving a living state at a terminal node, with an electronic output generated to indicate the recommended course of treatment.
Furthermore, the patent includes various claims related to the genetic profile of the subject, such as genotypes impacting oncogenes, pharmacokinetics, and drug sensitivity. The method involves analyzing characteristics like somatic mutations, tissue of origin, tumor burden, drug sensitivity, and stage, often determined through assaying cell-free nucleic acid molecules. The approach also includes monitoring changes in somatic mutations over time and administering the recommended treatment course to the subject. Additionally, the patent highlights the use of machine learning algorithms like Hidden Markov Models to enhance decision-making processes and improve treatment outcomes based on predictive models generated from a comprehensive database of genetic variants and medical information.
To know more about GlobalData’s detailed insights on Guardant Health, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
